AstraZeneca Adds 14,784 Shares Under Employee Schemes on LSE Main Market
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
AstraZeneca ( (GB:AZN) ) has issued an announcement.
AstraZeneca has admitted 14,784 additional ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market, bringing its total shares in issue to 1,551,024,534. The new shares, fully fungible with existing stock, were issued between 1 June and 30 June 2026 under the company’s existing block admission to satisfy employee share schemes.
The incremental issuance under employee share plans reflects AstraZeneca’s continued use of equity-based incentives while having a negligible dilutive effect given the small size relative to total share capital. Maintaining an established block admission framework supports administrative efficiency and signals ongoing alignment of staff compensation with shareholder interests in a highly competitive biopharmaceutical talent market.
The most recent analyst rating on (GB:AZN) stock is a Buy
with a £16500.00 price target.
To see the full list of analyst forecasts on AstraZeneca stock,
see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying fundamentals (profitability, margins, and returns) and a constructive earnings update with reiterated guidance and meaningful pipeline progress. These positives are partly offset by weak technical momentum, moderate valuation, and near-term cash/debt pressures tied to higher investment and payments.
To see Spark’s full report on AZN stock,
click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK, specialising in the discovery, development and commercialisation of prescription medicines. Its portfolio focuses on Oncology, Rare Disease and broader BioPharmaceuticals, including cardiovascular, renal, metabolic, respiratory and immunology therapies, with products sold in more than 125 countries.
Average Trading Volume: 2,154,421
Technical Sentiment Signal: Strong Buy
Current Market Cap: £218.7B
For a thorough assessment of AZN stock, go to TipRanks’ Stock Analysis page.
